The Psychiatric Genomics Consortium is one of the largest and most innovative and productive experiments in the history of psychiatry. The central idea of the PGC is leverage global collaboration to advance genetic discovery of biologically, clinically, and therapeutically meaningful insights.
The PGC continues to unify the field and attract outstanding scientists to its central mission. The PGC consists of 800+ investigators from 150+ institutions in 40+ countries. As of the end of 2019, PGC work has led to 320 papers. Many papers appeared in high-profile journals (Nature 3, Cell 5, Science 2, Nature Genetics 27, Nature Neuroscience 9, Mol Psych 37, Biol Psych 25, JAMA Psych 12). Summary statistics are freely available, and our findings have fueled analyses by non-PGC investigators and fostered the careers of many junior scientists.
The PGC studies 11 psychiatric disorders including ADHD, Alzheimer’s disease, autism, bipolar disorder, eating disorders, major depressive disorder, obsessive-compulsive disorder/Tourette syndrome, post-traumatic stress disorder, schizophrenia, substance use disorders, and all other anxiety disorders. These psychiatric disorders have exceptionally high morbidity, mortality, and personal/societal costs. As nearly all are syndromes that lack pathological or biological defining features, understanding their genetic basis is one of the most significant problems in medicine.
PGC investigators are passionate about open, inclusive, participatory, and democratic science. We are committed to rapid progress, reproducibility, and open science.
The PGC has received funding from many sources but has always relied heavily on the goodwill of its members and their donated effort. The establishment and genotyping of individual cohorts were supported by a wide range of national, international, and commercial funders.